Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)‘s stock had its “overweight” rating restated by Piper Jaffray Companies in a research note issued to investors on Thursday, November 2nd, The Fly reports. They presently have a $14.71 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $188.00. Piper Jaffray Companies’ price objective would indicate a potential downside of 88.33% from the stock’s previous close.
Several other research analysts also recently commented on the company. Needham & Company LLC reissued a “buy” rating and issued a $85.00 target price (down from $98.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, September 7th. Zacks Investment Research upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating and set a $88.00 target price for the company in a research report on Wednesday, July 12th. BMO Capital Markets reiterated an “outperform” rating and set a $99.00 target price (down previously from $105.00) on shares of Alnylam Pharmaceuticals in a research report on Wednesday, September 6th. Instinet assumed coverage on shares of Alnylam Pharmaceuticals in a research report on Friday, September 15th. They set a “reduce” rating and a $56.00 target price for the company. Finally, Leerink Swann reissued a “market perform” rating and issued a $72.00 price target (down previously from $83.00) on shares of Alnylam Pharmaceuticals in a report on Friday, September 8th. They noted that the move was a valuation call. Three investment analysts have rated the stock with a sell rating, six have issued a hold rating and seventeen have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $114.57.
Alnylam Pharmaceuticals (ALNY) traded down $4.26 during trading on Thursday, hitting $126.06. The stock had a trading volume of 131,912 shares, compared to its average volume of 1,132,432. Alnylam Pharmaceuticals has a twelve month low of $35.98 and a twelve month high of $147.63. The company has a debt-to-equity ratio of 0.14, a quick ratio of 9.83 and a current ratio of 9.83.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.11). The firm had revenue of $17.10 million for the quarter, compared to analyst estimates of $28.15 million. Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. The firm’s quarterly revenue was up 24.8% compared to the same quarter last year. During the same period last year, the business earned ($1.21) earnings per share. analysts anticipate that Alnylam Pharmaceuticals will post -5.22 EPS for the current year.
TRADEMARK VIOLATION WARNING: “Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Rating Reiterated by Piper Jaffray Companies” was originally published by BBNS and is the property of of BBNS. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://baseballnewssource.com/markets/piper-jaffray-companies-reiterates-overweight-rating-for-alnylam-pharmaceuticals-inc-alny/1751326.html.
In related news, President Barry E. Greene sold 85,316 shares of the company’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $125.00, for a total transaction of $10,664,500.00. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, President Barry E. Greene sold 76,815 shares of the company’s stock in a transaction on Wednesday, September 20th. The shares were sold at an average price of $100.00, for a total transaction of $7,681,500.00. Following the completion of the sale, the president now directly owns 165,399 shares of the company’s stock, valued at approximately $16,539,900. The disclosure for this sale can be found here. Insiders have sold 215,797 shares of company stock valued at $25,035,072 in the last three months. 4.30% of the stock is owned by insiders.
Institutional investors have recently modified their holdings of the stock. Fayerweather Charles bought a new position in shares of Alnylam Pharmaceuticals in the 3rd quarter worth about $230,000. Watch Point Trust Co bought a new stake in Alnylam Pharmaceuticals during the 3rd quarter valued at about $235,000. Segall Bryant & Hamill LLC bought a new stake in Alnylam Pharmaceuticals during the 3rd quarter valued at about $235,000. Boston Private Wealth LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter valued at about $247,000. Finally, QS Investors LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 59.7% during the 2nd quarter. QS Investors LLC now owns 2,408 shares of the biopharmaceutical company’s stock valued at $192,000 after acquiring an additional 900 shares during the last quarter. Institutional investors own 92.73% of the company’s stock.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.